Skip to main content
. Author manuscript; available in PMC: 2025 Dec 24.
Published in final edited form as: Sleep Med. 2025 Oct 14;136:106853. doi: 10.1016/j.sleep.2025.106853

Fig. 2.

Fig. 2.

Sleep Apnea-Specific Hypoxic Burden (SASHB). Percentage change from baseline in SASHB. Data are geometric means (coefficient of variation, %) expressed as the time spent in event-related oxygen desaturation per hour of sleep (% min/hr). Data points from baseline to Week 52 for Study 1 and Study 2 are shown according to the weeks since randomization, derived from a mixed-model-for-repeated-measures analysis for the efficacy estimand, using Log transformation. Data points are LSMean ± SE. **p ≤ 0.010; ***p ≤ 0.001 versus placebo. LSMean = least-squares mean; PBO = placebo; SASHB = Sleep Apnea-Specific Hypoxic Burden; SE = standard error; TZP = tirzepatide maximum tolerated dose (MTD, 10 mg or 15 mg once weekly).